Extendicare (TSE:EXE – Get Free Report) had its target price hoisted by equities researchers at TD Securities from C$15.00 to C$19.00 in a report released on Thursday,BayStreet.CA reports. TD Securities’ price objective would indicate a potential downside of 0.05% from the company’s current price.
Several other research analysts have also weighed in on EXE. Cibc World Mkts raised Extendicare to a “strong-buy” rating in a research report on Monday, September 22nd. National Bankshares increased their price objective on shares of Extendicare from C$16.10 to C$17.50 and gave the company an “outperform” rating in a research report on Wednesday, October 8th. CIBC set a C$18.00 target price on shares of Extendicare and gave the company an “outperform” rating in a research note on Monday, September 22nd. Finally, National Bank Financial raised shares of Extendicare to a “strong-buy” rating in a research note on Wednesday, July 16th. Two investment analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of C$16.80.
Check Out Our Latest Stock Analysis on Extendicare
Extendicare Trading Up 3.1%
About Extendicare
Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC”) homes and one of the largest private-sector providers of publicly funded home health care services.
Further Reading
- Five stocks we like better than Extendicare
- 10 Best Airline Stocks to Buy
- AMD to $300 Looks Easy—Here’s Why $500 Could Be Next
- How to Plot Fibonacci Price Inflection Levels
- $5B+ in Buybacks: What DraftKings, AppLovin, and Altria Are Telling You
- How to Use High Beta Stocks to Maximize Your Investing Profits
- 4 High-Yield Real Estate Stocks to Buy as Investors Get Defensive
Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.
